logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Michael Untch

interdisciplinary breast cancer center
H指数:108
被引数:7.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and treatment duration of ribociclib + nonsteroidal aromatase inhibitor in HR+/HER2− early breast cancer: a phase 3 randomized controlled trial (NATALEE)

来曲唑联合非甾体芳香化酶抑制剂在HR+/HER2−早期乳腺癌中的安全性和治疗持续时间：一项Ⅲ期随机对照试验（NATALEE）

Breast Cancer Research
IF5.6
2026-08-040
OAAI
H. S. Rugo; N. Harbeck; G. N. Hortobagyi; J. O’Shaughnessy; C.-S. Huang; M. Martin; D. Juric; B. Pistilli; B. Xu; M. De Laurentiis; M. Untch; K. Afenjar; M. Gao; Z. Li; N. Bolotova; S. Waters; C. Barrios
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials

远处无病生存期作为早期乳腺癌新辅助治疗随机试验中总生存期的替代终点：GBG和AGO-B研究组试验的合并分析

The Lancet Oncology
IF0
2025-11-240
PRE
Fabio Conforti; Johannes Holtschmidt; Valentina Nekljudova; Isabella Sala; Eleonora Pagan; Christine Solbach; Michael Untch; Carsten Denkert; Vincenzo Bagnardi; Laura Pala; Peter A Fasching; Andreas Schneeweiss; Hans-Joachim Lück; Giuseppe Viale; Tommaso De Pas; Marion van Mackelenbergh; Jens Huober; Volkmar Müller; Theresa Link; Thomas Karn
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival☆

HR阳性/HER2阴性早期乳腺癌患者的辅助瑞博西lib联合非甾体类芳香化酶抑制剂治疗：NATALEE试验5年随访的有效性结局及更新后的总生存期☆

ESMO Open
IF8.3
2025-10-170
OAAI
J. Crown; D. Stroyakovskii; D.A. Yardley; C.-S. Huang; P.A. Fasching; A. Bardia; S. Chia; S.-A. Im; M. Martin; B. Xu; C.H. Barrios; M. Untch; R. Moroose; S.A. Hurvitz; G.N. Hortobagyi; D.J. Slamon; F. Visco; G. Spera; J.P. Zarate; D. Halligan; Z. Li; S. Loi
Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study

乳腺癌患者接受阿贝西利或瑞博西利辅助治疗的患病率与预后：一项全国性基于人群的研究

The Lancet Regional Health - Europe
IF0
2025-09-290
OAAI
Xingrong Liu; Behnaz Binicy; Balazs Acs; Louise Eriksson Bergman; Sibylle Loibl; Michael Gnant; Michael Untch; Antonios Valachis; Jonas Bergh; Johan Hartman; Theodoros Foukakis; Alexios Matikas
AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025

AGO乳腺癌委员会关于乳腺癌手术治疗的建议：妇科肿瘤工作组（AGO）2025年更新

European Journal of Surgical Oncology
IF2.9
2025-09-170
PREAI
Toralf Reimer; Thorsten Kuehn; Volkmar Mueller; Nina Ditsch; Tanja Fehm; Ute-Susann Albert; Rupert Bartsch; Ingo Bauerfeind; Vesna Bjelic-Radisic; Jens-Uwe Blohmer; Wilfried Budach; Peter Dall; Eva Maria Fallenberg; Peter A. Fasching; Michael Friedrich; Bernd Gerber; Oleg Gluz; Nadia Harbeck; Andreas Hartkopf; Joerg Heil; Juliane Hoerner-Rieber; Jens Huober; Wolfgang Janni; Hans-Heinrich Kreipe; David Krug; Sherko Kuemmel; Sibylle Loibl; Diana Lueftner; Michael Patrick Lux; Nicolai Maass; Christoph Mundhenke; Tjoung-Won Park-Simon; Mattea Reinisch; Kerstin Rhiem; Achim Rody; Marcus Schmidt; Andreas Schneeweiss; Florian Schuetz; Hans-Peter Sinn; Christine Solbach; Erich-Franz Solomayer; Elmar Stickeler; Christoph Thomssen; Michael Untch; Marion van Mackelenbergh; Isabell Witzel; Achim Woeckel; Rachel Wuerstlein; Maggie Banys-Paluchowski; Marc Thill
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer

在接受一线CDK4/6抑制剂治疗后，转移性激素受体阳性、HER2阴性乳腺癌患者选择化疗方案的预后影响

European Journal of Cancer
IF7.1
2025-08-050
OA
Laura L. Michel; Philipp Ziegler; Philipp Kreis; Andreas D. Hartkopf; Markus Wallwiener; Lothar Häberle; Nelson John; Hans-Christian Kolberg; Peyman Hadji; Hans Tesch; Johannes Ettl; Diana Lüftner; Volkmar Müller; Erik Belleville; Pauline Wimberger; Hans-Martin Enzinger; Hanna Huebner; Sabrina Uhrig; Carolin C. Hack; Petra Krabisch; Peter A. Fasching; Rachel Wuerstlein; Michael Untch; Nina Ditsch; Alexander Hein; Wolfgang Janni; Florin-Andrei Taran; Michael P. Lux; Diethelm Wallwiener; Sara Y. Brucker; Tanja N. Fehm; Andreas Schneeweiss; Chloë Goossens; Tobias Engler
Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2− breast cancer and residual disease after neoadjuvant chemotherapy☆

PENELOPE-B试验的最终生存结果，该试验探讨了帕博西利（palbociclib）与安慰剂对比用于新辅助化疗后具有高危HR+/HER2−乳腺癌且存在残留病灶患者的治疗。

Annals of Oncology
IF65.4
2025-03-240
PRE
S. Loibl; M. Martin; H. Bonnefoi; M. Untch; S.-B. Kim; H.D. Bear; J.A. García-Sáenz; M. Melé Olivé; N. Mc Carthy; K. Gelmon; C.M. Kelly; S.-A. Im; T. Reimer; M. Martinez-Janez; Z. Zhang; M. Toi; L. Provencher; H.S. Rugo; M. Gnant; A. Makris; F. Marmé
Radar reflectors for marking of target lymph nodes in initially node-positive patients receiving neoadjuvant chemotherapy for breast cancer-a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial
BREAST CANCER RESEARCH AND TREATMENT
IF3
2025-02-200
PRE
Banys-Paluchowski, Maggie; Hartmann, Steffi; Basali, Timo; Gasparri, Maria Luisa; de Boniface, Jana; Gentilini, Oreste Davide; Cakmak, Gueldeniz Karadeniz; Ditsch, Nina; Stickeler, Elmar; Schlichting, Ellen; Rubio, Isabel; Peintinger, Florentia; Untch, Michael; Mau, Christine; Federspiel, Frederike Klaassen; Bucher, Susanne; Ramaker, Kerstin; Paluchowski, Peter; Bauer, Lelia; Riemer, Sabine; Langanke, Dagmar; Leuf, Tanja Durpektova; Schnabel, Jens; von Abel, Ekkehard; Solbach, Christine; Ovalle, Sonja Caradenas; Hilmer, Kerstin; Bjelic-Radisic, Vesna; Stahl, Nicole; Sanchez-Mendez, Jose I.; Hagen, Vibeke; Hansen, Marit Helene; Krawczyk, Natalia; Sezen, Bilge Aktas; Jursik, Katharina; Thill, Marc; Kolberg, Hans-Christian; Reimer, Toralf; Ruf, Franziska; Wihlfahrt, Kristina; Rief, Angelika; Berger, Tomasz; Schmidt, Esther; Tauber, Nikolas; Froehlich, Sarah; Kuehn, Thorsten
Efficacy and safety of ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in older patients (pts) with HR+/HER2-early breast cancer (EBC) in NATALEE

来那替尼（RIB）联合非甾体类芳香化酶抑制剂（NSAI）在NATALEE研究中，对激素受体阳性、人表皮生长因子受体2阴性早期乳腺癌（EBC）老年患者（pts）的疗效与安全性。

ANNALS OF ONCOLOGY
IF65.4
2024-09-011
PRE
Untch, M.; Yardley, D.; Im, S-A.; Pluard, T.; Hart, L.; Crown, J. P.; Freyer, G.; Zamagni, C.; Lopez-Barajas, I. Blancas; Parnizari, F.; Gao, M.; Amin, K.; Hu, H.; Rugo, H. S.
Neoadjuvant chemotherapy in inflammatory breast cancer: A meta-analysis of 10 trials of the German Breast Group (GBG)

炎性乳腺癌的新辅助化疗：德国乳腺癌组（GBG）10项试验的Meta分析

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Michel, L.; Untch, M.; Schneeweiss, A.; Solbach, C.; Blohmer, J-U.; Fasching, P. A.; Wimberger, P.; Hanusch, C.; Rezai, M.; Denkert, C.; Lueck, H-J.; Huober, J.; Schmatloch, S.; Rhiem, K. E.; Just, M.; Link, T.; Ladda, E.; Rey, J.; Holtschmidt, J.; Loibl, S.
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
NPJ BREAST CANCER
IF7.6
2024-07-130
OAAI
Fasching, Peter A.; Hu, Chunling; Hart, Steven N.; Ruebner, Matthias; Polley, Eric C.; Gnanaolivu, Rohan D.; Hartkopf, Andreas D.; Huebner, Hanna; Janni, Wolfgang; Hadji, Peyman; Tesch, Hans; Uhrig, Sabrina; Ettl, Johannes; Lux, Michael P.; Lueftner, Diana; Wallwiener, Markus; Wurmthaler, Lena A.; Goossens, Chloe; Mueller, Volkmar; Beckmann, Matthias W.; Hein, Alexander; Anetsberger, Daniel; Belleville, Erik; Wimberger, Pauline; Untch, Michael; Ekici, Arif B.; Kolberg, Hans-Christian; Hartmann, Arndt; Taran, Florin-Andrei; Fehm, Tanja N.; Wallwiener, Diethelm; Brucker, Sara Y.; Schneeweiss, Andreas; Haeberle, Lothar; Couch, Fergus J.
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
2024-06-243
OAAI
Dent, Rebecca; Cortes, Javier; Pusztai, Lajos; McArthur, Heather; Kuemmel, Sherko; Bergh, Jonas; Denkert, Carsten; Park, Yeon Hee; Hui, Rina; Harbeck, Nadia; Takahashi, Masato; Untch, Michael; Fasching, Peter A.; Cardoso, Fatima; Haiderali, Amin; Jia, Liyi; Nguyen, Allison Martin; Pan, Wilbur; O'Shaughnessy, Joyce; Schmid, Peter
Palbociclib combined with endocrine treatment in hormone receptorpositive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B
ESMO OPEN
IF8.3
2024-06-011
OAAI
Marme, F.; Martin, M.; Untch, M.; Thode, C.; Bonnefoi, H.; Kim, S. b.; Bear, H.; Mc Carthy, N.; Gelmon, K.; Garcia-Saenz, J. A.; Kelly, C. M.; Reimer, T.; Valota, O.; Toi, M.; Rugo, H. S.; Gnant, M.; Makris, A.; Bassy, M.; Zhang, Z.; Furlanetto, J.; Nekljudova, V.; Loibl, S.
CDH1 mutations predict resistance to neoadjuvant taxane therapy
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Knappskog, Stian; Helwa, Reham; Rachakonda, Sivaramakrishna; Gansmo, Liv B.; Denkert, Carsten; Yates, Lucy R.; Solbach, Christine; Untch, Michael; Sinn, Bruno V.; Litmeyer, Anne-Sophie; Ataseven, Beyhan; Huober, Jens; Wedge, David C.; Karn, Thomas; Nikolaienko, Oleksii; Marme, Frederik; Fasching, Peter A.; Eikesdal, Hans Petter; Stickeler, Elmar; Schem, Christian; Jank, Paul; van Mackelenbergh, Marion; Muller, Volkmar; Felder, Baerbel; Holtschmidt, Johannes; Campbell, Peter J.; Loibl, Sibylle; Lonning, Per
Ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2-early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial
CANCER RESEARCH
IF16.6
2024-05-023
PRE
Hortobagyi, Gabriel; Stroyakovsky, Daniil; Yardley, Denise; Huang, Chiun-Shen; Fasching, Peter A.; Crown, John; Bardia, Aditya; Chia, Stephen; Im, Seock-Ah; Martin, Miguel; Loi, Sherene; Xu, Binghe; Hurvitz, Sara; Barrios, Carlos; Untch, Michael; Moroose, Rebecca; Visco, Frances; Parnizari, Federico; Ghaznawi, Farhat; Li, Zheng; Waters, Sorcha; Chakravartty, Arunava; Slamon, Dennis
Germline mutation status of BRCA1/2 and other breast cancer predisposition genes as predictive and prognostic biomarker: Results of the GeparX study (GeparX-BRCA)
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Schmutzler, Rita K.; Link, Theresa; Hahnen, Eric; Reinisch, Mattea; Hauke, Jan; Just, Marianne; Untch, Michael; Ernst, Corinna; Stotzer, Oliver; Fasching, Peter A.; Kayali, Mohamad; Wimberger, Pauline; Schneeweiss, Andreas; Schmidt, Sandra; Seiler, Sabine; Jackisch, Christian; Thill, Marc; Rhiem, Kerstin; Denkert, Carsten; Nekljudova, Valentina; Holtschmidt, Johannes; Blohmer, Jens-Uwe; Loibl, Sibylle

研究方向

暂未获取到该数据
S
Sibylle Loibl
H 指数:131论文数:1,517被引数:9.5万
A
Andreas Schneeweiß
H 指数:98论文数:1,658被引数:5.2万
C
Carsten Denkert
H 指数:116论文数:1,286被引数:6.9万
P
Peter A. Fasching
H 指数:121论文数:2,055被引数:7.9万
J
Jens Huober
H 指数:79论文数:904被引数:3.3万
C
Christian Jackisch
H 指数:87论文数:832被引数:4.1万
G
Gϋnter von Minckwitz
H 指数:110论文数:1,106被引数:6.1万
J
Jens‐Uwe Blohmer
H 指数:74论文数:803被引数:3.2万
C
Claus Hanusch
H 指数:44论文数:299被引数:1.4万
H
Hans Tesch
H 指数:67论文数:753被引数:2.0万